Amphivena Therapeutics
Treatments to address hematologic malignancies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $62.0m | Series C | |
| Total Funding | 000k | ||
Related Content
Amphivena Therapeutics is a biotechnology company that operates in the healthcare sector, specifically in the field of immuno-oncology. The company's primary focus is on the development of innovative therapies to treat hematologic malignancies, which are cancers that affect the blood, bone marrow, and lymph nodes.
Amphivena's business model revolves around the research, development, and commercialization of novel therapeutics. The company's primary clients are patients suffering from hematologic malignancies, and it operates in the global pharmaceutical market. The company generates revenue through the development and sale of its therapeutic products.
Amphivena's flagship product, AMV564, is a T cell engager that is currently in clinical trials. This product is designed to engage the patient's immune system to destroy cancer cells, offering a potential new treatment option for patients with hematologic malignancies.
In summary, Amphivena Therapeutics is a biotech company that develops innovative therapies for the treatment of hematologic malignancies. The company operates in the global pharmaceutical market, serving patients suffering from these types of cancers. Its revenue is generated through the development and sale of its therapeutic products.
Keywords: Biotechnology, Healthcare, Immuno-oncology, Hematologic Malignancies, Therapeutics, Pharmaceutical Market, Patients, Cancer Treatment, Revenue Generation, Clinical Trials.